Neobe Therapeutics Raises $6.8M Seed for Tumour Access
Pedro Correa de Sampaio and Annelise Soulier built Neobe Therapeutics around the tissue surrounding a tumour. Their company engineers bacteria to change that environment, pursuing a way to help immune cells and existing cancer treatments reach places that dense fibrous material can keep out of reach.
The UK biotech announced a $6.8M Seed round, also reported as £5M, on November 10, 2026. ARC Ventures led, joined by Faber, Macmillan Ventures, Proven Connect, Empirical Ventures and returning investor 2048 Ventures. The financing supports preclinical development of NEO22 toward a planned investigational new drug filing in 2028.
That puts a treatment-access proposition inside the financing story. Neobe is developing a potential companion to therapies whose usefulness depends partly on what happens around the cancer cells. Its scientific and commercial assignment follows the same difficult question: which tumour environments can be changed enough for another treatment to work better?
Why Neobe is engineering the tumour environment
The company's technology description starts with immune exclusion. In some solid tumours, a dense extracellular matrix limits the movement of immune cells and therapeutic molecules. Finding a relevant drug target does not, by itself, settle whether a treatment can reach that target in the right setting.
Neobe uses synthetic biology to engineer tumour-colonising bacteria that express a payload locally. The organism is intended to reach the tumour and carry out its work there, changing parts of the surrounding environment. That local activity is central to the development proposition: the company wants to make the tissue more accessible while controlling where its therapeutic intervention occurs.
For a cancer-drug developer, the attraction would be an additional way to influence the conditions in which its medicine operates. That is an interpretation of Neobe's approach, rather than evidence of a particular pharmaceutical contract. A useful combination would need to connect the right bacterial programme, tumour setting and partner treatment, with evidence supporting the contribution of each.
The founders bring different parts of that problem into the same company. Correa de Sampaio is cofounder and CEO; Soulier is cofounder and CSO. The company describes their backgrounds in tumour-microenvironment research and bacterial engineering, respectively. Their working relationship gives Neobe a specific scientific starting point for deciding what the bacteria should do once they arrive.
What the research establishes
A 2026 paper in Molecular Cancer Therapeutics examines engineered bacteria that deliver hyaluronidase, an enzyme that breaks down hyaluronan in the tumour environment. The research involved Neobe, the University of Cyprus and Barts Cancer Institute, among the listed affiliations. It investigated mouse models and reports changes in tumour mechanics, vascular function, immune infiltration and responses to checkpoint inhibitors.
The response varied with the model. The study connects outcomes in relatively stiff breast tumours with baseline stiffness and matrix composition, while describing different associations in less stiff colorectal models. That variability is useful information for development: a platform aimed at the tumour environment must understand the environment it is entering.
It also gives the company a demanding selection problem. A broad claim about solid tumours can conceal important differences between tissues, immune conditions and treatment combinations. The research makes those differences part of the investment question, because a reproducible response in a defined setting gives future clinical work something more precise to investigate.
These are preclinical findings. Human safety and clinical benefit require their own evidence, and the published research does not establish treatment effectiveness in patients. The commercial significance at this stage is the specificity of the hypothesis Neobe can take forward: altering access may change the performance of another therapy, and the tissue characteristics may help explain where that approach deserves investigation.
How the financing changes development
The Seed capital gives Neobe a stated programme of preclinical work for NEO22 and a planned 2028 IND filing. That is a development target, with regulatory submission still ahead. In its announcement, the company also describes an additional tranche intended to fund a first-in-human trial; the release does not disclose its size or terms.
Laura Chow has been appointed CMO to oversee clinical development, according to the same announcement. Her arrival brings clinical planning into a company still advancing preclinical science. Decisions about the eventual patient setting and combination strategy have consequences for the work being designed now, which gives the appointment a role beyond adding another executive title to a funding release.
The syndicate also includes Macmillan Ventures, the investment arm of Macmillan Cancer Support. Its participation places a cancer-care investor alongside the venture firms backing Neobe. That relationship adds context to who is financing the work, without establishing that a patient outcome has already been achieved.
There is earlier institutional history behind the round. Neobe's February 2024 company announcement reported $2.34M in financing alongside a separate Innovate UK grant award. It also traces the company's 2021 formation to a venture creation alliance between Deep Science Ventures and Cancer Research Horizons. The current financing continues a development effort that has already moved through company creation, early funding and published research.
The company being built around combination treatment
Neobe's proposition creates a relationship with the medicines it may eventually accompany. A drug developer evaluating the platform would need to understand how bacterial activity changes a treatment's performance in a particular setting. That makes combination evidence and tumour selection central to the potential business, rather than supporting details added after the platform story.
The immediate operating work remains concrete: advance NEO22, deepen the preclinical evidence and prepare the clinical-development plan around the intended filing. Neobe's current careers page lists no open positions, so the financing should not be read as a published recruitment campaign. The company has described strengthening its leadership, with Chow's appointment providing a named example.
For the founders, the funding extends a scientific choice made at the company's formation: work on the conditions surrounding the cancer cell. For prospective development partners, the same choice becomes a question about their own therapy and the tissue in which they need it to perform. Neobe now has more capital to carry that conversation from laboratory results into the design of NEO22's path toward patients.
Frequently Asked Questions
Why is the tissue surrounding a tumour important to Neobe’s approach?
Dense extracellular material can restrict access by immune cells and therapeutic molecules in some solid tumours. Neobe is developing engineered bacteria intended to remodel parts of that environment so other treatments can work in a more accessible setting.
What evidence supports Neobe’s bacterial platform?
A 2026 Molecular Cancer Therapeutics study investigated engineered bacteria and immunotherapy in mouse cancer models. It reported changes in tumour mechanics, immune infiltration and treatment response, with outcomes depending on the model. These findings do not establish clinical benefit in humans.
What does the planned 2028 IND filing represent?
Neobe says the Seed financing will support preclinical NEO22 development toward an investigational new drug filing in 2028. This is a planned regulatory submission, not a confirmed treatment approval or patient-trial start date.
How is Neobe’s first-in-human work being financed?
The company announced a $6.8M Seed round, also reported as £5M, to support preclinical development and leadership capacity. Its announcement describes an additional tranche for a first-in-human trial without disclosing the tranche’s size or terms.
Why could tumour selection matter to a future Neobe combination therapy?
The published preclinical research found different associations between treatment response, matrix properties and immune-cell composition across models. This makes the specific tumour environment relevant to choosing the bacterial programme and accompanying treatment for further development.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved